Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The pharmaceutical company’s stock declined 2.41% on the day covered by the report, despite strength elsewhere in the market, the outlet said.
THE APEX TIMES
THE APEX TIMES
A market report says Johnson & Johnson (JNJ) has moved to buy Firefly Bio in a deal valued at about $1 billion in cash, as investors weigh valuation, pipeline risk, and how new oncology bets fit into the company’s broader healthcare portfolio.
THE APEX TIMES
A new set of weight-loss results from Pfizer is sharpening competitive pressure in the anti-obesity market, according to a recent market report, even as Eli Lilly and Novo Nordisk continue to emphasize their own efficacy and side-effect profiles.
THE APEX TIMES
Even as big-budget headlines crowd the market, Eli Lilly is seeing stronger demand for its stock after a steep rise in earnings, with the move framed by market commentary as a potential “buy zone.”
THE APEX TIMES
Abridge said it is pairing its documentation-focused AI with Nvidia’s AI infrastructure and has drawn a strategic investment from Eli Lilly, aiming to expand capabilities for how clinicians capture and review patient conversations.
THE APEX TIMES
Eli Lilly says it will require better claims data reporting from hospitals seeking 340B discounted drug pricing, and will stop supplying the discount to facilities that do not comply.
THE APEX TIMES
A recent market note flagged strong recent performance in CVS Health stock, but offered limited specifics on the operational drivers behind Q1 results, leaving investors to weigh sustainability versus near-term momentum.
THE APEX TIMES
A fresh Wall Street push to own Eli Lilly (LLY) is gaining traction as June volatility whips markets and GLP-1 demand expectations lift the stock. Still, much of the bullish case depends on how durable results remain beyond the current hype cycle.
THE APEX TIMES
Guinness Global Innovators’ Q1 2026 investor letter for its Global Equity Income Fund highlighted Johnson & Johnson, pointing to improving market sentiment rather than company-specific guidance.
